MPTYY vs ARWR
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MPTYY · MERLIN PROPERTIES SOCIMI S.A. UNSPON ADR EACH REP 2 ORD SHS$27.22 ▲ 0.00%
ARWR · Arrowhead Pharmaceuticals$58.16 ▲ 1.22%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MPTYY -15.1%
- ARWR +45.9%
Head to head
| Metric | MPTYY | ARWR |
|---|---|---|
| Price | $27.22 | $58.16 |
| Change today | ▲ 0.00% | ▲ 1.22% |
| Market cap | $8.22B | $8.22B |
| Return, 3 months | -21.6% | -34.2% |
| Return, year to date | -5.7% | -12.4% |
| Return, 1 year | -15.1% | +48.3% |
| P/E (TTM) | 7.9 | – |
| P/B | 0.8 | 17.6 |
| P/E percentile vs own 5y | – | 31st |
| Dividend yield | 3.59% | – |
| Revenue growth (YoY, latest qtr) | – | +171.0% |
| Net profit growth (YoY) | – | -0.1% |
| Gross margin | – | – |
| Operating margin | – | -33.8% |
| Net margin | – | -47.8% |
| Return on equity | – | -64.8% |
| Analyst target vs. price | – | +87.4% |
| Analyst buy share | – | 92% |
| RSI (14) | 52 | 40 |
| 30-day volatility | 35.8% | 37.2% |
| Max drawdown, 1 year | -30.3% | -37.6% |
| Trend read | Leaning bullish | Strong downtrend |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- MPTYY is the largest of the group by market value.
- ARWR has returned the most over the past year.
- MPTYY has been the calmest stock over the last 30 days.